PDF(Pubmed)
Abstract：
In this editorial we comment on the article by Pavlidis et al, published in the recent issue of the World Journal of Oncology. We focus on the recent contributions in the management of anaplastic thyroid carcinoma, highlighting the importance of surgery and radiotherapy as first line therapies in its management and the introduction of new systemic therapies beyond chemotherapy, focused on molecular alterations, an essential step in the diagnosis and included in clinical guidelines for the selection of the ideal treatment. In contrast to other neoplasms, immunotherapy, is still beginning in studies of this pathology with encouraging results. Therefore, multimodal management of the pathology together with new drugs seems to be the logical step to increase the survival of this neoplasm.
摘要：
在这篇社论中，我们评论了Pavlidis等人的文章，发表在最近一期的《世界肿瘤学杂志》上。我们关注的是最近在治疗间变性甲状腺癌方面的贡献，强调手术和放疗作为一线治疗的重要性，并引入化疗以外的新的全身疗法，专注于分子改变，诊断的重要步骤，并包括在临床指南中选择理想的治疗方法。与其他肿瘤相比，免疫疗法，仍在开始对这种病理学的研究，并取得了令人鼓舞的结果。因此,病理的多模式管理以及新药似乎是增加这种肿瘤生存率的合理步骤。
